Qiagen N.V. (QGEN)
Market Cap | 10.16B |
Revenue (ttm) | 2.04B |
Net Income (ttm) | 373.39M |
Shares Out | 216.56M |
EPS (ttm) | 1.69 |
PE Ratio | 27.71 |
Forward PE | 19.51 |
Dividend | $1.51 (3.25%) |
Ex-Dividend Date | Jul 2, 2025 |
Volume | 2,411,083 |
Open | 47.35 |
Previous Close | 46.50 |
Day's Range | 46.62 - 47.38 |
52-Week Range | 37.63 - 51.88 |
Beta | 0.64 |
Analysts | Buy |
Price Target | 51.01 (+8.72%) |
Earnings Date | Aug 5, 2025 |
About QGEN
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and... [Read more]
Financial Performance
In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price target is $51.01, which is an increase of 8.72% from the latest price.
News

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAsta...

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICT...

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICT...

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICT...

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis
Diagnostics now outperform Life Sciences due to academic funding cuts, making Qiagen's defensive profile more attractive in the current market. Qiagen offers stable growth, high profitability, and low...

Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN) Q2 2025 Earnings Conference Call August 6, 2025 9:30 AM ET Company Participants John Gilardi - Vice President of Corporate Communications & Investor Relations Roland Sackers -...

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced solid results for Q2 2025 that exceeded the outlook, and increased the fu...

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enri...

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to release results for Q2 2025 and hold webcast.

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman ...

Qiagen and Gencurix Enter Clinical Diagnostics Partnership
The companies said Wednesday the partnership combines Qiagen's QIAcuityDx platform, a digital polymerase chain reaction system, with Gencurix's expertise in assay development for oncology tests.

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assa...

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration t...

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors
NEW YORK--(BUSINESS WIRE)--Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Sta...

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partner...

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
BOULDER, Colo. , Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic,...

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of ...

Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential
QGEN has a relatively well-diversified portfolio across four segments on Sample Technologies, PCR/NA Amplification, Genomics/NGS, and Diagnostic Solutions. Their QIAstat-Dx's multiplex syndromic panel...

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
VENLO, the Netherlands & TEL AVIV, Israel--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has signed a definitive agreement to acquire Genoox,...

Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Berna...

QIAGEN announces plans for transition in leadership of Supervisory Board
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to ...

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today confirmed strong Q1 2025 results in line with the preliminary announcement and ...

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual c...

Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value
Management at Qiagen has done the hard things right, but there is now an opportunity for the company to grow faster and in a more focused way.

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPC...